Literature DB >> 12428205

Congenital adrenal hyperplasia: 11beta-hydroxylase deficiency.

Michael Peter1.   

Abstract

The most potent corticosteroids are 11beta-hydroxylated compounds. In humans, two cytochrome P450 isoenzymes with 11beta-hydroxylase activity, catalyzing the biosynthesis of cortisol and aldosterone, are present in the adrenal cortex. CYP11B1, the gene encoding 11beta-hydroxylase (P450c11), is expressed in high levels in the zona fasciculata and is regulated by adrenocorticotropic hormone (ACTH). CYP11B2, the gene encoding aldosterone synthase (P450c11Aldo), is expressed in the zona glomerulosa under primary control of the renin-angiotensin system. The substrate for P450c11 is 11-deoxycortisol. Mutations in CYP11B1 cause congenital adrenal hyperplasia (CAH) due to 11beta-hydroxylase deficiency. This disorder is characterized by androgen excess and hypertension and is autosomal recessively inherited. Classical and nonclassical forms of 11beta-hydroxylase deficiency can be distinguished. Studies in heterozygotes for classical 11beta-hydroxylase deficiency show inconsistent results with no or only mild hormonal abnormalities (elevated plasma levels of 11-deoxycortisol after ACTH stimulation). Molecular genetic studies of the CYP11B1 gene in 11beta-hydroxylase deficiency have led to the identification of several mutations. Transfection experiments showed loss of enzyme activity in vitro. Molecular genetic studies have practical importance for the prenatal diagnosis of virilizing CAH forms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12428205     DOI: 10.1055/s-2002-35389

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  8 in total

Review 1.  Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency.

Authors:  Krupali Bulsari; Henrik Falhammar
Journal:  Endocrine       Date:  2016-12-07       Impact factor: 3.633

2.  Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency: description of a new mutation, R384X.

Authors:  Audrey Mary Matallana-Rhoades; Juan David Corredor-Castro; Francisco Javier Bonilla-Escobar; Bony Valentina Mecias-Cruz; Liliana Mejia de Beldjena
Journal:  Colomb Med (Cali)       Date:  2016-09-30

Review 3.  Hypertension and adrenal disorders.

Authors:  Wassim Chemaitilly; Robert C Wilson; Maria I New
Journal:  Curr Hypertens Rep       Date:  2003-12       Impact factor: 5.369

Review 4.  Adrenocortical hypertension.

Authors:  Angelo Capricchione; Nathaniel Winer; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

5.  Mineralocorticoid hypertension.

Authors:  Vishal Gupta
Journal:  Indian J Endocrinol Metab       Date:  2011-10

6.  Steroid Metabolism in Children and Adolescents With Obesity and Insulin Resistance: Altered SRD5A and 20α/20βHSD Activity.

Authors:  Marta Sumińska; Rafał Podgórski; Piotr Fichna; Marta Fichna
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-26       Impact factor: 5.555

7.  Adrenocortical hypertension.

Authors:  Angelo Capricchione; Nathaniel Winer; James R Sowers
Journal:  Curr Urol Rep       Date:  2006-01       Impact factor: 2.862

8.  A Chinese patient with 11β-hydroxylase deficiency due to novel compound heterozygous mutation in CYP11B1 gene: a case report.

Authors:  Xianxian Yuan; Lin Lu; Shi Chen; Jun Jiang; Xiangqing Wang; Zhihui Liu; Huijuan Zhu; Hui Pan; Zhaolin Lu
Journal:  BMC Endocr Disord       Date:  2018-09-21       Impact factor: 2.763

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.